Roadmap to a Proteogenomic Cancer Atlas – An NCI Program

Date(s) - 8 May 2013
10:00 AM - 11:30 AM

The Biodesign Institute at ASU

The Bioidesign Institute at Arizona State University

Wednesday, May 8, 10 a.m.

Dr. Henry Rodriguez, Director of the Office of Cancer Clinical Proteomics Research, National Cancer Institute/National Institutes of Health
The Biodesign’s Virginia G. Piper Center for Personalized Diagnostics is hosting this seminar.
Location:  Biodesign Institute, Auditorium B105, 727 E. Tyler St., Tempe, AZ 85287.



Guest Presenter:

Henry Rodriguez, Ph.D., M.B.A.

Director, Office of Cancer Clinical Proteomics Research

Office of the Director, National Cancer Institute

Senior Scientific Officer, National Institutes of Health


Roadmap to a Proteogenomic Cancer Atlas – An NCI Program


The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), has established a consortium of research centers that are focusing on identifying proteins that derive from cancer genomes. The Clinical Proteomic Tumor Analysis Consortium (CPTAC) adds to NCI’s ongoing initiatives in molecular biology technology-based research programs, such as The Cancer Genome Atlas (TCGA), that comprehensively characterize tumors and make its findings publicly. Initiatives such as TCGA have characterized and sequenced the genomic alterations from several types of cancer that are providing a catalog of alterations in a cancer genome and setting the stage for the development of more molecular interventions that attack cancer cells based on their specific genetic makeup. CPTAC is leveraging its state-of-the-art, proteomic technologies to comprehensively translate cancer genomes to cancer proteomes. A unique feature of CPTAC is the utilization of genomically characterized biospecimens (such as those from TCGA) in conjunction with an independent prospective biospecimen cohort to confirm unique biological findings. Assays, protocols, and data produced from this program will be made available to the public. This seminar will discuss the questions being addressed by the program and what it hopes to accomplish in furthering our  understanding of cancer biology